Goehring EL, Bohn RL, Pezzullo J, et al. - In atrial fibrillation / atrial flutter (AF/AFL) patients treated with dronedarone or other antiarrhythmic drugs (AADs), the risk of cardiovascular-related hospitalizations and death was compared in this epidemiological study with a retrospective cohort design. Using propensity score (PS), matching of AF/AFL patients with incident dronedarone fills to incident users of other AADs was done. There were 6,349 Dronedarone users (91.2% of all eligible) and 12,698 Other AAD users in the PS-matched cohort. Hospitalization for cardiovascular (CV) reasons within 24 months following the first study drug fill was the primary study outcome. Hospitalization for CV causes or all-cause death during follow-up was the secondary composite outcome. Findings revealed a significantly lower risk of CV hospitalizations as well as the composite CV hospitalization / death from any cause in AF/AFL patients initiated on dronedarone vs other AADs.